Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
107.58
+2.55 (2.43%)
At close: Feb 11, 2026, 4:00 PM EST
106.97
-0.61 (-0.57%)
After-hours: Feb 11, 2026, 7:15 PM EST
Guardant Health Revenue
Guardant Health had revenue of $265.20M in the quarter ending September 30, 2025, with 38.50% growth. This brings the company's revenue in the last twelve months to $902.57M, up 30.38% year-over-year. In the year 2024, Guardant Health had annual revenue of $739.02M with 31.04% growth.
Revenue (ttm)
$902.57M
Revenue Growth
+30.38%
P/S Ratio
14.80
Revenue / Employee
$446,595
Employees
2,021
Market Cap
13.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 739.02M | 175.07M | 31.04% |
| Dec 31, 2023 | 563.95M | 114.41M | 25.45% |
| Dec 31, 2022 | 449.54M | 75.89M | 20.31% |
| Dec 31, 2021 | 373.65M | 86.92M | 30.32% |
| Dec 31, 2020 | 286.73M | 72.36M | 33.75% |
| Dec 31, 2019 | 214.38M | 123.74M | 136.52% |
| Dec 31, 2018 | 90.64M | 40.80M | 81.85% |
| Dec 31, 2017 | 49.84M | 24.59M | 97.40% |
| Dec 31, 2016 | 25.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Labcorp Holdings | 13.77B |
| Quest Diagnostics | 11.04B |
| ICON Public Limited Company | 8.10B |
| Illumina | 4.34B |
| Mettler-Toledo International | 4.03B |
| Charles River Laboratories International | 4.02B |
| Waters | 3.17B |
| Exact Sciences | 3.08B |
GH News
- 8 days ago - Guardant Health to Participate in Upcoming Investor Conferences - Business Wire
- 9 days ago - Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions - Business Wire
- 13 days ago - Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Business Wire
- 13 days ago - Alger Small Cap Focus Fund Q4 2025 Portfolio Update - Seeking Alpha
- 16 days ago - Guardant Health: Look For Explosive Revenue Growth Ahead - Seeking Alpha
- 16 days ago - Alger Small Cap Growth Fund Q4 2025 Portfolio Update - Seeking Alpha
- 19 days ago - Artisan Small Cap Fund Q4 2025 Portfolio Activity - Seeking Alpha
- 20 days ago - FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer - Benzinga